D-0727-2022 Class III Terminated

Recalled by Taro Pharmaceuticals U.S.A., Inc. — Hawthorne, NY

FDA drug recall D-0727-2022 was initiated by Taro Pharmaceuticals U.S.A., Inc. on Feb 25, 2022 and is designated Class III. Reason for recall: Failed Content Uniformity Specifications: Out-of-specification result for the Betamethasone Dipropionate assay of a stability sample The recall status is terminated (terminated Sep 9, 2024). Affected quantity: 768 tubes.

Recall details

Product Type
Drugs
Report Date
Apr 6, 2022
Initiation Date
Feb 25, 2022
Termination Date
Sep 9, 2024
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
768 tubes

Product description

Clotrimazole and Betamethasone Dipropionate Cream USP, 1%/0.05%,15 g tubes, Rx only, Manufactured by: Taro Pharmaceuticals Industries Ltd. Haifa Bay, Israel 2624761, Distributed by: Taro Pharmaceuticals U.S.A., Inc. Hawthorne, NY 10532, NDC 51672-4048-1

Reason for recall

Failed Content Uniformity Specifications: Out-of-specification result for the Betamethasone Dipropionate assay of a stability sample

Distribution pattern

Product was distributed to one retail consignee in NY.

Code information

Lot #: AC33883, Exp. Date June 2023

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0727-2022
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0727-2022. Report a data issue: hello@regdatalab.com.